Author

Audrey Mauguen

Memorial Sloan Kettering Cancer CenterORCID 0000-0003-3236-6093Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Adina GrunniD· 1 shared Alfred I. NeugutiD· 1 shared Allison R. RaineyiD· 1 shared Ana Isabel TergasiD· 1 shared Andrea CalifanoiD· 1 shared Andrew B. LassmaniD· 1 shared Andrew L. KungiD· 1 shared Armaan H. SiddiqueeiD· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperSystems Biology

Adina GrunnORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintOct 8, 2026

A Weighted Estimation Approach to Correct for Imperfect Mutation Detection Due to Intra-tumor Heterogeneity in Tumor Sequencing

Audrey Mauguen, Irina Ostrovnaya

The paper proposes a weighted estimation method to correct for imperfect mutation detection in tumor sequencing due to intra-tumor heterogeneity, reducing bias and type I error.

DOI 10.64898/2026.10.02.756288

whole-exome sequencingstatistical model

𝕏 PostBluesky

Systems BiologyCancer DiscoveryPeer-reviewedApr 16, 2023

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Prabhjot Singh Mundi, Filemon S. Dela Cruz, Adina Grunn…·Andrea Califano

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

51 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky